In summary, genetically modified ESCs can help address the consequences of dysregulation of DNMT1 on development and function of either GABAergic or glutamatergic neurons but may not present the overall picture of abnormalities associated with a mixture of neurons and other supporting cells in the brains of schizophrenia patients. The gene discussed is DNMT1; the disease is schizophrenia.